Foamix Unveils Cutting-Edge Technology Platform for Enhanced Delivery

Foamix Ltd. recently announced the development of a new breakthrough platform technology for targeted drug delivery that can enhance the delivery of drugs to skin and transdermal tissues and improve their efficacy.

The technology is suitable for a variety of drugs, including corticosteroids, retinoids, antibiotics, antifungal and antiviral agents, NSAIDs, and hormones; and can be used to treat skin disorders, eg, psoriasis, acne, rosacea, fungal and bacterial infections, as well as conditions that require transdermal delivery of drugs.

Nanoemulsions are submicron-sized emulsions that are under extensive investigation as drug carriers for improving the delivery of therapeutic agents. These are by far the most advanced nanoparticle systems for the systemic delivery of active pharmaceuticals for controlled drug delivery and targeting. These are the thermodynamically stable system in which two immiscible liquid (water and oil) are mixed to form a single phase by means of an appropriate surfactants or it mixes with a typical droplet size in the range of 20 to 200 nm. Nanoemulsions show great promise for the future of topical drug therapies and cosmetics.

Nano-emulsions have multiple advantages in the context of topical drug delivery:

Improved Solubility: Nanoemulsion is the approach to improve water solubility and ultimate bioavailability of lipophilic drugs. The nano-sized droplets leading to enormous interfacial areas associated with nanoemulsions would influence the transport properties of the drug, an important factor in sustained and targeted drug delivery.

Enhanced Bioavailability: Droplet size are nano, so surface area is higher, thus increases the rate of absorption and enhances bioavailability of drug.

Skin Penetration: Nanoemulsion also enhances permeation of drug through skin.

Improved Stability: Nanoemulsions protect the drug from hydrolysis and oxidation due to encapsulation in oil-droplet. It also provides taste-masking.

Suitable for Any Drug: Nanoemulsions can deliver both hydrophilic and lipophilic drugs.

Safety: The Foamix nanoemulsions are non-toxic and non-irritant.

As a technology leader in its field, Foamix collaborates with multinational and local pharmaceutical companies in the development of patent-protected, unique topical products using its versatile patent protected foam platforms.

“We are very excited to have this breakthrough technology platform. This is evidence of our commitment to developing a robust pipeline for the future of the company and for the benefit of our partners.” said Dov Tamarkin, PhD, Foamix’s CEO. “Having many different platform technologies with intellectual property protection enables Foamix to develop a new generation of pharmaceutical foam products, based either on new chemical entities or as life cycle management strategies for existing drugs.”

Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel products for dermatology, gynecology, as well as ophthalmic disorders. To date, Foamix has 54 granted patents worldwide, including 19 issued patents in the US. Additionally, the company has more than 135 pending patent applications worldwide, of which over 70 applications are filed in the US. For more information, visit www.foamix.co.il.